Prevention of nitroimidazole resistance in *Campylobacter pylori* by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies

C S GOODWIN,* B J MARSHALL,† E D BLINCOW,* D H WILSON,*
S BLACKBOURN,‡ M PHILLIPS¶

From the Departments of *Microbiology, †Gastroenterology and ‡Pharmacy, Royal Perth Hospital, Perth, and ¶the Medical Statistics Department, Curtin University of Technology, Bentley, Western Australia

SUMMARY One hundred patients with duodenal ulceration and *Campylobacter pylori* in their stomach were entered into a double blind placebo controlled prospective study. Treatment schedules were cimetidine and placebo, or cimetidine and tinidazole, or colloidal bismuth subcitrate (CBS) and placebo, or CBS and tinidazole. Seventeen per cent of isolates of *C pylori* obtained at the first endoscopy were resistant to tinidazole and 70% of the second isolates from patients given cimetidine and tinidazole became tinidazole resistant. Suspensions of nitroimidazole sensitive cultures of *C pylori* showed that three of 22 isolates had a nitroimidazole resistant subpopulation. In patients who healed and remained free of *C pylori* after treatment ulcers recurred less often than in patients who healed but retained *C pylori* (23% v 73% over 12 months, $p < 0.001$).

The spiral bacteria first cultured from the gastric mucosa of patients with histologically confirmed gastritis at Royal Perth Hospital in 1982¹ were originally named *Campylobacter pyloridis*,² but the revised name is now *Campylobacter pylori*.³ *C pylori* is highly susceptible to many antibiotics.^{2,4,5} We recently concluded a double blind, placebo controlled, prospective study of patients with duodenal ulceration and *C pylori* in their stomach, which included the nitroimidazole drug (tinidazole), given in addition to standard prophylaxis. We report the development of tinidazole resistance in a high proportion of the patients given tinidazole and cimetidine; the full clinical details of the study will be reported elsewhere. Some patients remained unhealed after 10 weeks of treatment and were then entered into an open study of various antibacterial regimens. Colloidal bismuth subcitrate (CBS) has a powerful bactericidal action against *C pylori*; the minimum inhibitory concentration of bismuth of *C pylori* is 8 mg/l,⁵ and ultrastructural studies of the gastric mucosa 75 minutes after administration of CBS have shown that most bacteria seem to have been killed.

Material and methods

PLACEBO CONTROLLED STUDY

Patients referred to one of us (BJM) for upper gut symptoms were examined endoscopically, and if a duodenal ulcer was seen gastric mucosal specimens were taken for histological examination and culture of *C pylori*. Biopsy specimens were examined by Gram stain and culture in the manner already described.⁶ Patients found to have a duodenal ulcer with *C pylori* (100 of 107 examined) were allocated to one of four treatment groups:

- 1 Cimetidine 400 mg twice daily for eight weeks, plus placebo for the first 10 days.
- 2 Cimetidine for eight weeks plus tinidazole 500 mg twice daily for the first 10 days.
- 3 CBS one tablet four times daily for eight weeks plus placebo for 10 days.
- 4 CBS for eight weeks plus tinidazole for the first 10 days.

Cimetidine is inactive against *C pylori*.⁵ The patients were allocated their drug treatment randomly by a computer program to ensure that similar types of patients of the same sex, age, previous duodenal ulcer history, and drug treatment were in each of the four groups.

OPEN STUDY

Each patient was examined endoscopically two, 14, 26, and 52 weeks after the end of the initial course of treatment, and at any time when gastric symptoms were experienced which suggested relapse of the duodenal ulcer. At any of these endoscopies, if a duodenal ulcer was found the patient was removed from the double blind study and entered into an open study of CBS for 14 days plus either oral amoxycillin 500 mg six hourly for seven or 14 days, or oral enteric coated pellets of erythromycin base 500 mg six hourly for 14 days.

SENSITIVITY TESTS

Isolates of *C. pylori* were tested by disc diffusion on blood agar for their sensitivity to tinidazole (5 µg), metronidazole (5 µg), and amoxycillin (2 µg). Sensitive strains were shown by a zone of inhibition of 25 mm, and resistant isolates gave no zone of growth inhibition.

The minimum inhibitory concentrations (MICs) of tinidazole and metronidazole against isolates from eight patients, before and after the development of resistance, were determined by a method already described.⁵ To determine the prevalence of a sub-population of tinidazole resistant bacteria within a sensitive culture 22 tinidazole sensitive strains were grown in liquid medium with shaking for 24 hours in a Campylobacter gas mixture. Then 0.6 ml was inoculated on to agar containing 8 mg/l metronidazole or 8 mg/l tinidazole. The plates were incubated in a Campylobacter gas mixture for five days, and colonies which grew were tested for their sensitivity to the nitroimidazoles.

Results

Among the 100 isolates of *C. pylori* obtained at the first endoscopies 17 were resistant to tinidazole and metronidazole; these included two in the group treated with cimetidine and tinidazole and five in the group treated with CBS and tinidazole. In the 27 other patients in the group treated with cimetidine and tinidazole the isolate became resistant in 19 (70%). In the 27 patients who received CBS and tinidazole the original isolate was tinidazole resistant in five patients, and *C. pylori* was not eliminated in four of these patients. In the remaining 22 patients *C. pylori* was eliminated in 20, and the isolate became tinidazole resistant in the other two.

Elimination of *C. pylori* from the stomach was achieved in only one of the 29 patients who received cimetidine and tinidazole. This was significantly different ($p < 0.001$, $\chi^2 = 55.4$).

The isolate of *C. pylori* that was sensitive at entry into the trial from eight patients was compared with

the isolate from the second biopsy specimen which showed nitroimidazole resistance. For the sensitive isolates the MICs to both metronidazole and tinidazole were less than 4 mg/l, and the MICs of resistant isolates were 16 mg/l or greater.

Twenty two cultures of *C. pylori* in liquid medium were plated on solid medium containing metronidazole or tinidazole 8 mg/l. After five days of incubation three of the cultures showed between 100 and 200 colonies of *C. pylori* on each plate. The resistances were confirmed by disc diffusion and determination of MIC.

PLACEBO CONTROLLED STUDY

The computer program allocated 22 patients to receive cimetidine and placebo, 29 to receive cimetidine and tinidazole, 22 to receive CBS and placebo, and 27 to receive CBS and tinidazole. In the open study 15 patients received CBS plus amoxycillin for seven days, 25 patients received CBS plus amoxycillin for 14 days, and 18 patients received CBS plus erythromycin for 14 days.

The addition of antibacterial treatment to antiulcer treatment did not give a higher initial healing rate of duodenal ulcer in the various groups. Thirty three of the 100 patients remained unhealed after the eight weeks, 36 relapsed after healing, and 31 remained healed for 12 months. Initial healing was accompanied by elimination of *C. pylori* in 26 patients, and in six of these the duodenal ulcer recurred. In 41 patients the duodenal ulcer healed but *C. pylori* were still present, and in 30 patients the duodenal ulcer recurred. This was highly significant ($p < 0.001$). Clearance of *C. pylori* in 28 patients was accompanied by ulcer healing in 26, but only 41 of the patients who remained infected with *C. pylori* showed ulcer healing ($p < 0.001$).

OPEN STUDY

The healing rates of the duodenal ulcers and the number of patients in whom *C. pylori* was eliminated are shown for the three antibiotic regimens in the table. Eighteen patients were given erythromycin but one patient developed severe side effects so that he could take no more than two days of treatment. Interestingly, amoxycillin plus CBS for 14 days

Healing of duodenal ulceration and elimination of C. pylori in patients treated with CBS and antibiotic

CBS plus:	No of patients	Ulcer healed (%)	<i>C. pylori</i> eliminated (%)
Amoxycillin for seven days	15	13 (87)	7 (47)
Amoxycillin for 14 days	25	17 (68)	11 (44)
Erythromycin	17	15 (88)	11 (65)

achieved about the same elimination rate as amoxycillin plus CBS for seven days.

All the patients treated with tinidazole remained free of systemic side effects, but some complained of a metallic taste in the mouth. A few patients treated with amoxycillin complained of abdominal discomfort and a few of diarrhoea. After endoscopy patients developed symptoms which could be attributed more to endoscopy than to antibiotic, and if the patients persisted taking the antibiotic their symptoms receded. Seven patients treated with erythromycin complained bitterly of abdominal pain.

Discussion

In the double blind placebo controlled prospective trial tinidazole was chosen as the antibacterial agent for several reasons. Previous experience indicated that patients who already complained of indigestion did not experience any additional symptoms when given tinidazole. Bismuth plus tinidazole had proved the most effective of various combinations in a preliminary study. It was known that a small proportion of isolates of *C pylori* were resistant to tinidazole, but our finding that tinidazole plus cimetidine resulted in 70% of the isolates becoming resistant to tinidazole was unexpected. We also found that in the absence of tinidazole, when *C pylori* had not been eliminated, the subsequent isolates of *C pylori* occasionally became tinidazole resistant. Thus resistance can occur spontaneously, and this was confirmed by our studies in vitro; when cultures of nitroimidazole sensitive *C pylori* were plated on agar containing nitroimidazole, three of 22 culture growths showed large numbers of nitroimidazole resistant colonies on the agar. Nine of these resistant strains were retested after subculture on to plain media without antibiotics and one strain reverted to nitroimidazole sensitivity. This is reminiscent of rifampicin resistance and fusidic acid resistance in cultures of susceptible bacteria, when most cultures exhibit a small proportion of bacteria resistant to these antibiotics. Thus a nitroimidazole drug should never be given as the sole antibacterial treatment for *C pylori*, but when combined with CBS, nitroimidazole resistance did not occur so often; and in 84% of patients *C pylori* was eliminated.

The minimum inhibitory concentration of metronidazole against *C pylori* was reported by McNulty *et al* to be 0.5–8.0 mg/l on solid media.⁴ In liquid medium we found that the MIC₉₀ was 4.0 mg/l, the minimum bactericidal concentration for 90% of isolates was 16 mg/l, and isolates resistant to tinidazole had an MIC₉₀ of 32 mg/l.⁵ In the present study the MIC₉₀ of tinidazole against resistant isolates was 16 mg/l or greater.

The principal problem encountered in the treatment

of duodenal ulcers is the relapse rate, which can be as high as 100% in patients followed up for two years.⁸ In our double blind study recurrence of the duodenal ulcer after initial healing was detected by endoscopy in 73% of 41 patients in whom *C pylori* had not been eliminated, but when healing was accompanied by elimination of *C pylori* only six (23%) of patients relapsed ($p < 0.001$).

Thus effective antibacterial treatment with the elimination of *C pylori* significantly reduces the relapse rate of healed duodenal ulcers. We also found that initial clearance of *C pylori* was accompanied by ulcer healing in 26 (93%) of 28 patients, but when patients remained infected with *C pylori* only 41 (57%) showed ulcer healing ($p < 0.001$).

In the open study of TCB plus amoxycillin for 14 days *C pylori* was eliminated in less than seven (50%) of the patients. Beta lactam producing antibiotics penetrate cells less efficiently than other antibiotics⁹ and *C pylori* does not invade the gastric mucosa but is found on the surface of the mucosa, and so may be even less accessible to amoxycillin. Erythromycin penetrates cells better than amoxycillin and in 11 (65%) of patients we were able to eliminate *C pylori*. It is clear that a dual treatment regimen with CBS plus an appropriate antibiotic is much more effective at eliminating *C pylori* than either treatment with only CBS or an antibiotic alone.^{10–12} The organism lives in a sequestered niche¹² and thus repeated courses of antibiotics may be required to eliminate it.

We acknowledge a grant from the National Health and Medical Research Council of Australia for Dr B J Marshall. We thank Pfizer for supplies of tinidazole, placebo antibiotic and financial assistance. We thank Faye Coverley for secretarial help.

References

- 1 Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet* 1984;i:1311–5.
- 2 Marshall BJ, Royce H, Annear DI, *et al*. Original isolation of *Campylobacter pyloridis* from human gastric mucosa. *Microbios Letters* 1984;25:83–8.
- 3 Marshall BJ, Goodwin CS. Revised nomenclature for *C pyloridis*. *Int J Systems Bacteriol* 1987;37:68.
- 4 McNulty CAM, Dent J, Wise R. Susceptibility of clinical isolates of *Campylobacter pyloridis* to 11 antimicrobial agents. *Antimicrob Agents Chemother* 1985;28:837–8.
- 5 Goodwin CS, Blake P, Blincow E. The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against *Campylobacter pyloridis*. *J Antimicrob Chemother* 1986;17:309–14.
- 6 Goodwin CS, Blincow ED, Warren JR, Waters TE, Sanderson CR, Easton L. Evaluation of cultural techniques for isolating *Campylobacter pyloridis* from endoscopic biopsies of gastric mucosa. *J Clin Pathol* 1985;38:1127–31.

- 7 Marshall BJ, Armstrong JA, Francis G, Nokes NT, Lee SH. The antibacterial action of Bismuth in relation to *Campylobacter pyloridis* colonization and gastritis. *Digestion* 1987;37(suppl 2):16-30.
- 8 Bardhan K, Cole DS, Hawkins BW, Franks CR. Does treatment with cimetidine extended beyond initial healing of duodenal ulcer reduce the subsequent relapse rate? *Br Med J* 1982;284:621-3.
- 9 Jacobs RF, Wilson CB. Intracellular penetration and antimicrobial activity of antibiotics. *J Antimicrob Chemother* 1983;12(Suppl C):13-20.
- 10 Langenberg ML, Rauws EAJ, Schipper MEI, *et al.* The pathogenic role of *Campylobacter pyloridis* studied by attempts to eliminate these organisms. In: Pearson AD, Skirrow MB, Lior H, Rowe B, eds. *Campylobacter III: proceedings of the third international workshop on Campylobacter infections*. London: Public Health Laboratory Service, 1985:162-3.
- 11 McNulty CAM, Crump B, Gearity JC, *et al.* *Campylobacter pyloridis* and associated gastritis: investigator blind, placebo-controlled trial of bismuth salicylate and erythromycin ethylsuccinate. *Br Med J* 1986;293:645-9.
- 12 Goodwin CS, Armstrong JA, Marshall BJ. *Campylobacter pyloridis*, gastritis, and peptic ulceration. *J Clin Pathol* 1986;39:353-65.

Requests for reprints to: Professor C S Goodwin, Department of Microbiology, Royal Perth Hospital, Perth, Western Australia.